Online Resource May Increase Patient-Provider Discussions on Hereditary Breast and Ovarian Cancer Syndrome

Published Online: Monday, September 16, 2013
Follow Pharmacy_Times:
Online interactive tools may help women to increase their awareness and knowledge of family history, and encourage more patient-provider discussions on hereditary breast and ovarian cancer syndrome, according to study results published in the August 2013 issue of Patient Education and Counseling.

Hereditary breast and ovarian cancer syndrome is rare, and screening for it is only recommended for women with a strong family history of cancer. Most patients, however, are not aware of their family history and have difficulty understanding genetic concepts. Cancer in the Family, an online clinical decision support tool, was developed to help women calculate their risk for hereditary breast and ovarian cancer syndrome. To test the efficacy of the website, the researchers enrolled 48 patients and 9 providers to participate in the pilot study.

Almost all patients (96%) used the tool to calculate their personal risk, and 65% of those patients shared their results with providers. The website prompted 67% of participants to enter their complete family history and led 88% of patients to start conversations about hereditary breast and ovarian cancer syndrome risk and family history with their providers.

Although the tool increased patient awareness, the authors note that online resources should not replace conversations between patients and health care providers.

Related Articles
Citing a risk of spreading unsuspected cancer, the FDA is advising against the use of laparoscopic power morcellators in the removal of the uterus or fibroids in the majority of women.
Amgen has discontinued its studies on rilotumumab in advanced gastric cancer after an increased number of deaths were reported among patients receiving rilotumumab and chemotherapy, compared with those only undergoing chemotherapy.
Clinical practice guidelines for the diagnosis and treatment of certain types of cancer are surprisingly unstandardized.
A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.
Latest Issues
$auto_registration$